Royalty percentage "high teens" -
>>...Some analysts expressed surprise that Shire, Britain's third-biggest drugmaker, had branched into woundcare.
"We believe the success of this venture will be dependent upon Shire's ability, over the mid-to long-term, to build a woundcare speciality alongside a more traditional pharmaceuticals business," Bridgewell Securities analysts wrote in note to clients, saying they viewed the deal cautiously.
They agreed, however, that it was great news for Renovo, which also posted a first-half loss of 11 million pounds ($21.9 million).
"The deal terms achieved are outstanding," Nomura Code's Samir Devani said.
Ferguson said Renovo would decide at a later stage whether to find a partner for Europe, or to sell Juvista there itself.
He signalled the firm was likely to receive royalties on Juvista sales in a "high teens" percentage...<< |
